Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer
This study has been terminated.
Study NCT00055432
Information provided by Eli Lilly and Company
First Received: March 3, 2003
Last Updated: September 13, 2006
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
